{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Capsule+2&page=103",
    "query": {
      "intervention": "Capsule 2",
      "page": 103
    },
    "page_size": 10
  },
  "pagination": {
    "page": 103,
    "page_size": 10,
    "total_count": 5067,
    "total_pages": 507,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Capsule+2&page=104&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Capsule+2&page=102&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-18T13:59:07.154Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02895906",
      "title": "Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "22q11.2 Deletion Syndrome"
      ],
      "interventions": [
        {
          "name": "NFC-1",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aevi Genomic Medicine, LLC, a Cerecor company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 2,
      "start_date": "2016-11-28",
      "completion_date": "2017-04-20",
      "has_results": false,
      "last_update_posted_date": "2022-03-25",
      "last_synced_at": "2026-11-18T13:59:07.154Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02895906"
    },
    {
      "nct_id": "NCT01598272",
      "title": "Effects of a Proprietary Blend of Herbal Extract Supplement on Cellular Detoxification, Inflammation, and Cumulative Cognitive Index as Well as Gene Expression in Middle-Aged Adult Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Anti Aging"
      ],
      "interventions": [
        {
          "name": "Vitality product AM + Vitality product PM",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Pharmanex",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "73 Years",
        "sex": "FEMALE",
        "summary": "35 Years to 73 Years · Female only"
      },
      "enrollment_count": 95,
      "start_date": "2011-07",
      "completion_date": "2012-06",
      "has_results": false,
      "last_update_posted_date": "2014-12-11",
      "last_synced_at": "2026-11-18T13:59:07.154Z",
      "location_count": 1,
      "location_summary": "Orem, Utah",
      "locations": [
        {
          "city": "Orem",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01598272"
    },
    {
      "nct_id": "NCT01111955",
      "title": "Safety Study of BMS-823778 in Subjects With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "BMS-823778",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 62,
      "start_date": "2010-07",
      "completion_date": "2011-01",
      "has_results": false,
      "last_update_posted_date": "2015-10-12",
      "last_synced_at": "2026-11-18T13:59:07.154Z",
      "location_count": 3,
      "location_summary": "Hialeah, Florida • Olympia, Washington • Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Olympia",
          "state": "Washington"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01111955"
    },
    {
      "nct_id": "NCT03801148",
      "title": "A Study to Compare the Bioavailability (BA) of Dexlansoprazole Delayed-release Capsules",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "30 mg dexlansoprazole capsules manufactured at TOB",
          "type": "DRUG"
        },
        {
          "name": "30 mg dexlansoprazole capsules manufactured at TPC",
          "type": "DRUG"
        },
        {
          "name": "60 mg dexlansoprazole capsules manufactured at TOB",
          "type": "DRUG"
        },
        {
          "name": "60 mg dexlansoprazole capsules manufactured at TPC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 122,
      "start_date": "2019-01-10",
      "completion_date": "2019-04-09",
      "has_results": true,
      "last_update_posted_date": "2020-03-19",
      "last_synced_at": "2026-11-18T13:59:07.154Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03801148"
    },
    {
      "nct_id": "NCT04530747",
      "title": "Metabolic Effects of Metformin Therapy in Obstructive Sleep Apnea",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Sleep Apnea, Obstructive"
      ],
      "interventions": [
        {
          "name": "Metformin + PAP",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral capsule + PAP",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pennington Biomedical Research Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "35 Years to 65 Years"
      },
      "enrollment_count": 16,
      "start_date": "2021-01-28",
      "completion_date": "2021-11-30",
      "has_results": true,
      "last_update_posted_date": "2023-01-19",
      "last_synced_at": "2026-11-18T13:59:07.154Z",
      "location_count": 1,
      "location_summary": "Baton Rouge, Louisiana",
      "locations": [
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04530747"
    },
    {
      "nct_id": "NCT00963027",
      "title": "Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hypertension, Pulmonary",
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "Treprostinil diethanolamine",
          "type": "DRUG"
        },
        {
          "name": "Esomeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "United Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 30,
      "start_date": "2009-09",
      "completion_date": "2009-10",
      "has_results": false,
      "last_update_posted_date": "2010-03-08",
      "last_synced_at": "2026-11-18T13:59:07.154Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00963027"
    },
    {
      "nct_id": "NCT06717269",
      "title": "A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "NX-5948",
          "type": "DRUG"
        },
        {
          "name": "Esomeprazole",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Famotidine",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Digoxin",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin",
          "type": "DRUG"
        },
        {
          "name": "Quinidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nurix Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "19 Years to 55 Years"
      },
      "enrollment_count": 223,
      "start_date": "2024-11-30",
      "completion_date": "2026-05-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-28",
      "last_synced_at": "2026-11-18T13:59:07.154Z",
      "location_count": 2,
      "location_summary": "Phoenix, Arizona • Lincoln, Nebraska",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06717269"
    },
    {
      "nct_id": "NCT01072266",
      "title": "A Dose-escalation Study in Subjects With Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor",
        "Advanced Cancer",
        "Metastatic Cancer"
      ],
      "interventions": [
        {
          "name": "INCB028060",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2010-01",
      "completion_date": "2013-01",
      "has_results": false,
      "last_update_posted_date": "2017-11-22",
      "last_synced_at": "2026-11-18T13:59:07.154Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Nashville, Tennessee",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01072266"
    },
    {
      "nct_id": "NCT01445795",
      "title": "Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "200 mg INX-08189 Fasted",
          "type": "DRUG"
        },
        {
          "name": "Placebo QD Fasted",
          "type": "DRUG"
        },
        {
          "name": "100 mg INX-08189 QD",
          "type": "DRUG"
        },
        {
          "name": "Placebo QD",
          "type": "DRUG"
        },
        {
          "name": "100 mg INX-08189 with low-fat meal",
          "type": "DRUG"
        },
        {
          "name": "Placebo with low-fat meal",
          "type": "DRUG"
        },
        {
          "name": "100 mg INX-08189 BID Fasted",
          "type": "DRUG"
        },
        {
          "name": "Placebo BID Fasted",
          "type": "DRUG"
        },
        {
          "name": "ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 50,
      "start_date": "2011-09",
      "completion_date": "2012-05",
      "has_results": false,
      "last_update_posted_date": "2016-06-27",
      "last_synced_at": "2026-11-18T13:59:07.154Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01445795"
    },
    {
      "nct_id": "NCT06319339",
      "title": "Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Peripheral Artery Disease",
        "Peripheral Vascular Diseases",
        "Peripheral Arterial Disease",
        "Peripheral Arterial Occlusive Disease"
      ],
      "interventions": [
        {
          "name": "Vumerity",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "50 Years to 75 Years"
      },
      "enrollment_count": 20,
      "start_date": "2024-11-14",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-24",
      "last_synced_at": "2026-11-18T13:59:07.154Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06319339"
    }
  ]
}